Nature Awards – the Spinoff price
September 4, 2024
Breast cancer prognostic test Digistain available to selected UK private patients with reimbursement from Bupa, WPA and Healix
November 27, 2024
We’re proud to share that our clinical validation study, published earlier this year in Breast Cancer Research and Treatment, has been recognised as one of the journal’s top-performing articles, ranked in the 97th percentile for popularity.
The study highlights ground-breaking findings:
The study reports the prognostic performance of Digistain® for risk classification in HR+, HER2- breast cancer.
Dive into the details of our study and findings here:
